FULVESTRANT Teva sol inj 250 mg/5ml ser pré 2 pce
7680664700022
CH-66470
L02BA03
07.16.2.
Reimbursement limitations:
FASLODEX
Traitements des patientes à la post-ménopause (ménopause naturelle ou induite) avec cancer du sein localement …
1 / 2
google
Details
- Product number
- 6647001
- CPT
- -
- Packaging group
- 2
- Unit
- Fertigspritze(n)
- Composition
- fulvestrantum 250 mg, ethanolum 96 per centum 500 mg, alcohol benzylicus 500 mg, benzylis benzoas 750 mg, ricini oleum raffinatum q.s. ad solutionem pro 5 ml corresp. ethanolum 12.16 % V/V.
Articles (1)
Fulvestrant-Teva 250mg/5ml, Injektionslösung in einer Fertigspritze
Injektionslösung
2
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
250.0 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
500.0 MG | Substance | HBESI |
|
(N/A)
|
500.0 MG | Substance | HBESI |
|
(N/A)
|
750.0 MG | Substance | HBESI |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
12.16 PVV | Substance | HBESI |
Reimbursement information
Public price
CHF 329.05
Specialties list
Yes
Generic
Yes
Reimbursement limitation
SL addition date:
01/01/2021
Authorization holder
Teva Pharma AG
4051 Basel
Authorization information
- Swissmedic authorization number
- 66470
- Drug name
- Fulvestrant-Teva, Injektionslösung in einer Fertigspritze
- Galenic form
- LSPA
- ATC Code
- L02BA03
- Authorization status
- Z
- Dispensation category
- B
- First authorization
- 27/07/2017
- Authorization expiration date
- 31/12/9999
- IT number
- 07.16.2.
- Domain
- Human medicine
Packaging details
- Description (FR)
- FULVESTRANT Teva sol inj 250 mg/5ml ser pré 2 pce
- Description (DE)
- FULVESTRANT Teva Inj Lös 250 mg/5ml Fertspr 2 Stk
- Market launch
- 27/07/2017
- Narcotic (BTM)
- No